Site icon pharmaceutical daily

Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Market Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Global Clinical Trials Review, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Global Clinical Trials Review, 2022 provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ).

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

Reasons to Buy

Key Topics Covered:

Companies Mentioned

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/t18c1m

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version